Nantahala Capital Management’s Structure Therapeutics GPCR Stock Holding History

Nantahala Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-368,553	Closed	-$10.3M	–	165
2025 Q3	$10.3M	Buy	368,553 +200,000	+119%	+$3.98M	0.36%	63
2025 Q2	$3.5M	Hold	168,553	–	–	0.14%	106
2025 Q1	$2.92M	Sell	168,553 -52,447	-24%	-$1.28M	0.12%	100
2024 Q4	$5.99M	Buy	221,000 +50,000	+29%	+$1.77M	0.26%	70
2024 Q3	$7.51M	Buy	+171,000	New	+$6.61M	0.38%	55
2023 Q3	–	Sell	-50,000	Closed	-$2.08M	–	140
2023 Q2	$2.08M	Hold	50,000	–	–	0.2%	76
2023 Q1	$1.19M	Buy	+50,000	New	+$1.17M	0.09%	94

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nantahala Capital Management's GPCR Position: Q4 2025 in Review

Nantahala Capital Management sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 368,553 shares — an estimated $10.3M sold.

Nantahala Capital Management first reported a position in GPCR in Q1 2023 and held it in 7 quarters. The position peaked at $10.3M in Q3 2025. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

Nantahala Capital Management reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
Nantahala Capital Management sold 368,553 Structure Therapeutics shares in Q4 2025, an estimated $10.3M.
Nantahala Capital Management first reported a position in Structure Therapeutics in Q1 2023 and held it in 7 quarters.
Nantahala Capital Management's Structure Therapeutics position peaked at $10.3M in Q3 2025.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.